Strong market-implied odds of 94.4% against a new coronavirus pandemic in 2026 stem primarily from ongoing CDC and WHO surveillance data showing SARS-CoV-2 circulation at endemic levels, with test positivity below 2%, emergency department visits at 0.1%, and declining infection trends across most U.S. states as of early May. Subvariants such as XFG lineages and BA.3.2 exhibit high transmissibility yet cause mild illness comparable to prior Omicron strains, without meeting criteria for Variants of Concern or pandemic thresholds. Historical patterns of seasonal respiratory viruses and robust global monitoring further support trader consensus that the virus remains manageable rather than escalating. Realistic challenges include emergence of a highly immune-evasive strain or unexpected surge in vulnerable populations, which could shift odds if case counts or severity metrics rise sharply before year-end.